WallStSmart

Hinge Health, Inc. (HNGE)vsMangoceuticals, Inc. Common Stock (MGRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hinge Health, Inc. generates 155803% more annual revenue ($646.34M vs $414,580). MGRX leads profitability with a 0.0% profit margin vs -78.9%. HNGE earns a higher WallStSmart Score of 36/100 (F).

HNGE

Hold

36

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.69

MGRX

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 2.57

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.2%10/10

Revenue surging 47.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

MGRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
43.4x2/10

Trading at 43.4x book value

Return on EquityProfitability
-197.2%2/10

ROE of -197.2% — below average capital efficiency

EPS GrowthGrowth
-68.4%2/10

Earnings declined 68.4%

MGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.35M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.

Bull Case : MGRX

The strongest argument for MGRX centers on Price/Book, Debt/Equity.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : MGRX

The primary concerns for MGRX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

HNGE profiles as a hypergrowth stock while MGRX is a value play — different risk/reward profiles.

HNGE is growing revenue faster at 47.2% — sustainability is the question.

HNGE generates stronger free cash flow (43M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HNGE scores higher overall (36/100 vs 23/100) and 47.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Mangoceuticals, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.

Visit Website →

Want to dig deeper into these stocks?